Recently, the Department of Energy’s National Nuclear Security Administration (NNSA) issued a cooperative agreement with the fourth U.S. company for the production of Mo-99 without highly enriched uranium. The company located in Corvallis, Oregon, Northwest Medical Isotopes received a commitment of $15 million in matching funds from the DOE’s NNSA. Previously agreements were reached with three other U.S. companies, Niowave (Lansing, Michigan), NorthStar Medical Radioisotopes (Beloit, Wisconsin) and SHINE Medical Technologies (Janesville, Wisconsin). Adding another company to the list for the production of Mo-99 here in the USA is a good sign that we are moving forward to secure a reliable supply of Tc-99m labeled radiopharmaceuticals for the continuing provision of nuclear medicine and nuclear cardiology imaging services.